Symbols / CTOR
CTOR Chart
About
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 97.99M |
| Enterprise Value | 94.49M | Income | -23.64M | Sales | 3.94M |
| Book/sh | 0.69 | Cash/sh | 0.08 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 24.84 | P/B | 1.61 | P/C | — |
| EV/EBITDA | — | EV/Sales | 23.96 | Quick Ratio | 0.25 |
| Current Ratio | 0.83 | Debt/Eq | 6.51 | LT Debt/Eq | — |
| EPS (ttm) | -0.31 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-13 08:00 | ROA | -13.96% |
| ROE | -47.41% | ROIC | — | Gross Margin | 79.99% |
| Oper. Margin | -133.17% | Profit Margin | 0.00% | Shs Outstand | 88.28M |
| Shs Float | 14.13M | Short Float | 5.46% | Short Ratio | 4.83 |
| Short Interest | — | 52W High | 6.19 | 52W Low | 0.55 |
| Beta | 3.10 | Avg Volume | 442.08K | Volume | 157.34K |
| Target Price | $6.00 | Recom | Buy | Prev Close | $1.14 |
| Price | $1.11 | Change | -2.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$6.00
Mean price target
2. Current target
$1.11
Latest analyst target
3. DCF / Fair value
$-5.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.11
Low
$6.00
High
$6.00
Mean
$6.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-23 | up | Maxim Group | Hold → Buy | $6 |
| 2025-05-23 | down | Maxim Group | Buy → Hold | — |
| 2024-11-27 | init | Maxim Group | — → Buy | $3 |
| 2024-08-13 | main | EF Hutton | Buy → Buy | $6 |
- Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Finviz ue, 24 Feb 2026 15
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire ue, 09 Dec 2025 08
- First LYMPHIR cancer drug sales bring in $3.9M for Citius Oncology - Stock Titan Fri, 13 Feb 2026 13
- Citius Oncology (CTOR) Expands LYMPHIR Distribution to Europe Through Exclusive Agreement With Uniphar - Insider Monkey ue, 24 Feb 2026 14
- Citius Oncology, Inc. (NASDAQ:CTOR) stock most popular amongst public companies who own 79%, while individual investors hold 14% - Yahoo Finance Fri, 26 Sep 2025 07
- CITIUS ONCOLOGY Q1 2026 Earnings Preview: Recent $CTOR Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Wed, 11 Feb 2026 08
- Citius Oncology, Inc. (NASDAQ:CTOR): Is Breakeven Near? - simplywall.st ue, 13 Jan 2026 08
- Earnings Breakdown: Citius Oncology Q1 - Benzinga Fri, 13 Feb 2026 13
- Uniphar to offer LYMPHIR via access programs for CTCL in Europe - Stock Titan Wed, 11 Feb 2026 08
- When Will Citius Oncology, Inc. (NASDAQ:CTOR) Become Profitable? - Yahoo Finance hu, 06 Nov 2025 08
- Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire Wed, 10 Sep 2025 07
- Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIRâ„¢ Commercial Launch - Stock Titan Mon, 20 Oct 2025 07
- Citius Oncology (Nasdaq: CTOR) inks Er-Kim deal as LYMPHIR reaches 19 markets - Stock Titan hu, 04 Dec 2025 08
- Q4 2025 U.S. Launch Planned: Citius Oncology Signs Exclusive EVERSANA Deal to Commercialize LYMPHIR - Stock Titan hu, 16 Oct 2025 07
- New cancer drug LYMPHIR launches as Citius raises $36M for commercialization - Stock Titan ue, 23 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGRATH DENNIS M | Director | — | 2025-09-19 00:00:00 | D |
| 1 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGRATH DENNIS M | Director | — | 2025-09-19 00:00:00 | D |
| 2 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCGRATH DENNIS M | Director | — | 2025-09-19 00:00:00 | D |
| 3 | 1700000 | — | — | Stock Award(Grant) at price 0.00 per share. | MAZUR LEONARD L | Chief Executive Officer | — | 2025-09-19 00:00:00 | D |
| 4 | 1700000 | — | — | Stock Award(Grant) at price 0.00 per share. | MAZUR LEONARD L | Chief Executive Officer | — | 2025-09-19 00:00:00 | D |
| 5 | 1700000 | — | — | Stock Award(Grant) at price 0.00 per share. | MAZUR LEONARD L | Chief Executive Officer | — | 2025-09-19 00:00:00 | D |
| 6 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | DUTIA SUREN G | Director | — | 2025-09-19 00:00:00 | D |
| 7 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | DUTIA SUREN G | Director | — | 2025-09-19 00:00:00 | D |
| 8 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | DUTIA SUREN G | Director | — | 2025-09-19 00:00:00 | D |
| 9 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | MAYERSOHN JOEL DAVID | Director | — | 2025-09-19 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -23.49M | -20.57M | -12.12M | -4.86M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -24.76M | -21.15M | -12.70M | -5.43M |
| EBITDA | -23.49M | -20.57M | -12.12M | -4.86M |
| EBIT | -23.49M | -20.57M | -12.12M | -4.86M |
| NetInterestIncome | -181.66K | 0.00 | ||
| InterestExpense | 218.03K | 0.00 | ||
| InterestIncome | 36.37K | 0.00 | ||
| NormalizedIncome | -24.76M | -21.15M | -12.70M | -5.43M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -24.76M | -21.15M | -12.70M | -5.43M |
| TotalExpenses | 23.52M | 20.57M | 12.12M | 4.86M |
| TotalOperatingIncomeAsReported | -23.52M | -20.57M | ||
| DilutedAverageShares | 73.27M | 68.05M | 71.24M | 71.24M |
| BasicAverageShares | 73.27M | 68.05M | 71.24M | 71.24M |
| DilutedEPS | -0.34 | -0.31 | -0.18 | -0.08 |
| BasicEPS | -0.34 | -0.31 | -0.18 | -0.08 |
| DilutedNIAvailtoComStockholders | -24.76M | -21.15M | -12.70M | -5.43M |
| NetIncomeCommonStockholders | -24.76M | -21.15M | -12.70M | -5.43M |
| NetIncome | -24.76M | -21.15M | -12.70M | -5.43M |
| NetIncomeIncludingNoncontrollingInterests | -24.76M | -21.15M | -12.70M | -5.43M |
| NetIncomeContinuousOperations | -24.76M | -21.15M | -12.70M | -5.43M |
| TaxProvision | 1.06M | 576.00K | 576.00K | 576.00K |
| PretaxIncome | -23.70M | -20.57M | -12.12M | -4.86M |
| NetNonOperatingInterestIncomeExpense | -181.66K | 0.00 | ||
| InterestExpenseNonOperating | 218.03K | 0.00 | ||
| InterestIncomeNonOperating | 36.37K | 0.00 | ||
| OperatingIncome | -23.52M | -20.57M | -12.12M | -4.86M |
| OperatingExpense | 23.52M | 20.57M | 12.12M | 4.86M |
| ResearchAndDevelopment | 6.42M | 4.93M | 4.24M | 3.43M |
| SellingGeneralAndAdministration | 17.10M | 15.65M | 7.88M | 1.43M |
| GeneralAndAdministrativeExpense | 17.10M | 15.65M | 7.88M | 1.43M |
| OtherGandA | 8.78M | 8.15M | 5.92M | 1.43M |
| SalariesAndWages | 8.32M | 7.50M | 1.97M | 0.00 |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 83.51M | 71.55M | 71.24M | 71.24M |
| ShareIssued | 83.51M | 71.55M | 71.24M | 71.24M |
| NetDebt | 3.80M | |||
| TotalDebt | 3.80M | 3.80M | ||
| TangibleBookValue | -28.53M | -27.26M | -14.46M | -3.73M |
| InvestedCapital | 48.67M | 49.94M | 25.54M | 36.27M |
| WorkingCapital | -21.95M | -21.73M | -13.31M | -3.16M |
| NetTangibleAssets | -28.53M | -27.26M | -14.46M | -3.73M |
| CommonStockEquity | 44.87M | 46.14M | 25.54M | 36.27M |
| TotalCapitalization | 48.67M | 49.94M | 25.54M | 36.27M |
| TotalEquityGrossMinorityInterest | 44.87M | 46.14M | 25.54M | 36.27M |
| StockholdersEquity | 44.87M | 46.14M | 25.54M | 36.27M |
| RetainedEarnings | -64.04M | -39.28M | -18.13M | -5.43M |
| AdditionalPaidInCapital | 108.90M | 85.41M | 43.66M | 41.69M |
| CapitalStock | 8.35K | 7.16K | 6.75K | 6.75K |
| CommonStock | 8.35K | 7.16K | 6.75K | 6.75K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 56.08M | 38.23M | 22.20M | 6.42M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.59M | 5.53M | 1.15M | 576.00K |
| OtherNonCurrentLiabilities | -1.00 | |||
| NonCurrentDeferredLiabilities | 2.78M | 1.73M | 1.15M | 576.00K |
| NonCurrentDeferredTaxesLiabilities | 2.78M | 1.73M | 1.15M | 576.00K |
| LongTermDebtAndCapitalLeaseObligation | 3.80M | 3.80M | ||
| LongTermDebt | 3.80M | 3.80M | ||
| CurrentLiabilities | 49.49M | 32.70M | 21.05M | 5.85M |
| OtherCurrentLiabilities | 1.00 | |||
| PayablesAndAccruedExpenses | 49.49M | 32.70M | 21.05M | 5.85M |
| CurrentAccruedExpenses | 4.09M | 0.00 | 259.07K | 1.06M |
| Payables | 45.40M | 32.70M | 20.79M | 4.79M |
| OtherPayable | 22.65M | 28.40M | ||
| DuetoRelatedPartiesCurrent | 9.51M | 588.81K | 19.50M | 4.69M |
| AccountsPayable | 13.23M | 3.71M | 1.29M | 92.31K |
| TotalAssets | 100.94M | 84.37M | 47.73M | 42.69M |
| TotalNonCurrentAssets | 73.40M | 73.40M | 40.00M | 40.00M |
| GoodwillAndOtherIntangibleAssets | 73.40M | 73.40M | 40.00M | 40.00M |
| OtherIntangibleAssets | 73.40M | 73.40M | 40.00M | 40.00M |
| CurrentAssets | 27.54M | 10.97M | 7.73M | 2.69M |
| PrepaidAssets | 1.33M | 2.70M | 7.73M | 2.69M |
| Inventory | 22.29M | 8.27M | 0.00 | |
| FinishedGoods | 10.58M | 6.13M | ||
| WorkInProcess | 11.71M | 2.13M | ||
| CashCashEquivalentsAndShortTermInvestments | 3.92M | 112.00 | 0.00 | 0.00 |
| CashAndCashEquivalents | 3.92M | 112.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -11.24M | -4.87M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 3.80M | 0.00 | |
| IssuanceOfCapitalStock | 15.17M | 0.00 | ||
| CapitalExpenditure | -5.75M | -5.00M | ||
| EndCashPosition | 3.92M | 112.00 | 0.00 | 0.00 |
| BeginningCashPosition | 112.00 | 0.00 | 0.00 | 0.00 |
| ChangesInCash | 3.92M | 112.00 | ||
| FinancingCashFlow | 15.17M | 4.87M | 0.00 | |
| CashFlowFromContinuingFinancingActivities | 15.17M | 4.87M | 0.00 | |
| NetOtherFinancingCharges | 1.07M | |||
| NetCommonStockIssuance | 15.17M | 0.00 | ||
| CommonStockIssuance | 15.17M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 0.00 | 3.80M | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 3.80M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 3.80M | 0.00 | |
| InvestingCashFlow | -5.75M | -5.00M | 0.00 | |
| CashFlowFromContinuingInvestingActivities | -5.75M | -5.00M | 0.00 | |
| NetIntangiblesPurchaseAndSale | -5.75M | -5.00M | 0.00 | |
| PurchaseOfIntangibles | -5.75M | -5.00M | 0.00 | |
| OperatingCashFlow | -5.49M | 126.35K | 0.00 | 0.00 |
| CashFlowFromContinuingOperatingActivities | -5.49M | 126.35K | 0.00 | 0.00 |
| ChangeInWorkingCapital | 9.89M | 13.20M | 10.16M | 4.86M |
| ChangeInPayablesAndAccruedExpense | 22.54M | 16.43M | 15.20M | 5.85M |
| ChangeInAccruedExpense | 4.09M | -259.07K | -801.75K | 1.06M |
| ChangeInPayable | 18.45M | 16.69M | 16.00M | 4.79M |
| ChangeInAccountPayable | 9.52M | 2.42M | 1.20M | 92.31K |
| ChangeInPrepaidAssets | 0.00 | -1.10M | -5.04M | -990.18K |
| ChangeInInventory | -12.65M | -2.13M | 0.00 | |
| StockBasedCompensation | 8.32M | 7.50M | 1.97M | 0.00 |
| DeferredTax | 1.06M | 576.00K | 576.00K | 576.00K |
| DeferredIncomeTax | 1.06M | 576.00K | 576.00K | 576.00K |
| NetIncomeFromContinuingOperations | -24.76M | -21.15M | -12.70M | -5.43M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CTOR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|